BAJAJ FINSERV DIRECT LIMITED
Open Your FREE Demat Account Now!

Medicamen Organics Ltd. Share Price

NSE
BSE

NSE : MEDIORG

BSE : 0

Sector : Healthcare

N/A
indicator
1D
1M
3M
6M
1Y
5Y
empty graph

Day's Range

Day's Range

Low

₹0.00

High

₹0.00

Price Summary

Previous Close ₹27.00
Day's Range ₹0.00 - ₹0.00
Open ₹0.00
52 Week Range ₹20.05 - ₹49.70
Volume 0
Market Cap ₹0.00

Stocks Summary

Trade Value ( ₹ in Lacs)
Market Cap (₹ in Mn) 0.00
Dividend Yield(%) 0.00
Price/Earning (TTM) 7.81
TTM EPS (₹) 3.46
P/E Ratio 6.27
Book Value(₹) 1.08
PAT Margin (%) 10.60
Face Value (₹) 10.00
ROCE(%) 16.97

Financials

Particulars QTR FY (₹ in Millions) Annual FY (₹ in Millions)
Net sales N/A 252.72
Expenses N/A N/A
PBT N/A 44.37
Operating profit N/A 0.0
Net profit N/A 26.24

Shareholding Pattern

Promoters (% Holding)

59.73%

Mutual funds (% Holding)

0.00%

Non-Institution (% Holding)

38.56%

FI/Banks/Insurance (% Holding)

0.00%

Government (% Holding)

0.00%

FII

0.07%

About Medicamen Organics Ltd.

Founded 1995
Managing Director Bal Kishan Gupta
NSE Symbol MEDIORG

Peer Comparision

Stocks Name Market Cap (Cr)(₹) Market Price (₹) 52 Week Low-High (₹)
Sun Pharmaceutical Industries Ltd. 4,51,590.83 1,877.80 1,548.00 - 1,548.00
Divi's Laboratories Ltd. 1,83,511.79 6,903.00 5,636.50 - 5,636.50
Torrent Pharmaceuticals Ltd. 1,50,850.21 4,417.60 3,102.00 - 3,102.00
Apollo Hospitals Enterprise Ltd. 1,15,401.57 8,100.00 6,696.50 - 6,696.50
Cipla Ltd. 1,13,883.72 1,408.00 1,165.70 - 1,165.70
Dr. Reddy's Laboratories Ltd. 1,11,339.07 1,327.55 1,148.40 - 1,148.40
Lupin Ltd. 1,04,542.41 2,293.40 1,836.80 - 1,836.80
Max Healthcare Institute Ltd. 1,03,825.65 1,072.30 903.00 - 903.00
Mankind Pharma Ltd. 1,02,963.51 2,606.15 1,909.70 - 1,909.70
Zydus Lifesciences Ltd. 1,02,530.21 1,054.15 835.50 - 835.50
no-content No Records Found

Latest News

May
20
2026
EQUITY Posted on May 20th 2026

HealthCare Global Enterprises informs about statement of deviation or variation

Pursuant to the Listing Regulations, HealthCare Global Enterprises has confirmed that there were no deviations or variations in the utilisation of the proceeds raised through the Rights Issue of the Company during the quarter ended March 31, 2026, from the objects stated in the Letter of Offer dated February 24, 2026. In this regard, it has enclosed, as Annexure, the statement confirming that there was no deviation or variation in the utilisation of the aforesaid proceeds for the quarter ended March 31, 2026, from the objects stated in the Letter of Offer, in accordance with SEBI Circular No. CIR/CFD/CMD1/162/2019 dated December 24, 2019. The said statement has been duly reviewed by the Audit Committee of the Company. The above information is also available on the website of the Company and can be accessed at: https://www.hcgoncology.com/.

The above information is a part of company’s filings submitted to BSE.

Read More
May
20
2026
COMPANY Posted on May 20th 2026

Kopran - Quaterly Results

The Turnover for the quarter ended March 2026 of Rs. 1180.39 millions increase by 55.45% from Rs. 759.35 millions.Net Profit witnessed a 118.02% growth almost the double from Rs. 85.98 millions to Rs. 187.45  millions  of same quarter last year.Operating Profit saw a handsome growth to 275.89 millions from 142.04 millions in the quarter ended March 2026.
(Rs. in Million)
  Quarter ended Year to Date Year ended
  202603 202503 % Var 202603 202503 % Var 202603 202503 % Var
Sales 1180.39 759.35 55.45 3056.46 2710.10 12.78 3056.46 2710.10 12.78
Other Income 10.03 19.17 -47.68 19.99 59.04 -66.14 19.99 59.04 -66.14
PBIDT 275.89 142.04 94.23 495.75 445.60 11.25 495.75 445.60 11.25
Interest 11.72 12.58 -6.84 42.00 37.66 11.52 42.00 37.66 11.52
PBDT 264.17 129.46 104.06 453.75 407.94 11.23 453.75 407.94 11.23
Depreciation 13.44 12.39 8.47 49.81 49.99 -0.36 49.81 49.99 -0.36
PBT 250.73 117.07 114.17 403.94 357.95 12.85 403.94 357.95 12.85
TAX 63.28 31.09 103.54 99.94 89.38 11.81 99.94 89.38 11.81
Deferred Tax 5.45 3.74 45.72 9.58 3.06 213.07 9.58 3.06 213.07
PAT 187.45 85.98 118.02 304.00 268.57 13.19 304.00 268.57 13.19
Equity 482.86 482.86 0.00 482.86 482.86 0.00 482.86 482.86 0.00
PBIDTM(%) 23.37 18.71 24.95 16.22 16.44 -1.35 16.22 16.44 -1.35
Read More
May
20
2026
COMPANY Posted on May 20th 2026

Zydus Lifesciences - Quaterly Results

A decrease of about -35.72% in the sales to Rs. 37409.00 millions was observed for the quarter ended March 2026. The sales stood at Rs. 58196.00 millions during the similar quarter previous year.Profit after Tax for the quarter ended March 2026 saw a decline of -38.80% from Rs. 28137.00 millions to Rs. 17220.00  millions.The company reported a degrowth in operating Profit to 24842.00 millions from 39581.00 millions.
(Rs. in Million)
  Quarter ended Year to Date Year ended
  202603 202503 % Var 202603 202503 % Var 202603 202503 % Var
Sales 37409.00 58196.00 -35.72 114840.00 151163.00 -24.03 114840.00 151163.00 -24.03
Other Income 11430.00 1854.00 516.50 28962.00 9058.00 219.74 28962.00 9058.00 219.74
PBIDT 24842.00 39581.00 -37.24 55929.00 84325.00 -33.67 55929.00 84325.00 -33.67
Interest 1155.00 1554.00 -25.68 4829.00 4639.00 4.10 4829.00 4639.00 4.10
PBDT 22619.00 38027.00 -40.52 49431.00 79686.00 -37.97 49431.00 79686.00 -37.97
Depreciation 1509.00 1280.00 17.89 5612.00 5239.00 7.12 5612.00 5239.00 7.12
PBT 21110.00 36747.00 -42.55 43819.00 74447.00 -41.14 43819.00 74447.00 -41.14
TAX 3890.00 8610.00 -54.82 8221.00 16698.00 -50.77 8221.00 16698.00 -50.77
Deferred Tax -577.00 345.00 -267.25 -777.00 873.00 -189.00 -777.00 873.00 -189.00
PAT 17220.00 28137.00 -38.80 35598.00 57749.00 -38.36 35598.00 57749.00 -38.36
Equity 1006.00 1006.00 0.00 1006.00 1006.00 0.00 1006.00 1006.00 0.00
PBIDTM(%) 66.41 68.01 -2.36 48.70 55.78 -12.70 48.70 55.78 -12.70
Read More
May
20
2026
COMPANY Posted on May 20th 2026

Nephrocare Health Se - Quaterly Results

The Revenue for the quarter ended  March 2026 of Rs. 1643.33 millions grew by 13.32 % from Rs. 1450.12 millions.Profit for the quarter ended March 2026 rises by 91.96% to Rs. 108.88  millions from Rs. 56.72 millions.The company reported a good operating profit of 282.13 millions compared to 244.80 millions of corresponding previous quarter.
(Rs. in Million)
  Quarter ended Year to Date Year ended
  202603 202503 % Var 202603 202503 % Var 202603 202503 % Var
Sales 1643.33 1450.12 13.32 6297.43 5435.97 15.85 6297.43 5435.97 15.85
Other Income 61.35 27.32 124.56 154.34 156.31 -1.26 154.34 156.31 -1.26
PBIDT 282.13 244.80 15.25 1036.01 1105.14 -6.26 1036.01 1105.14 -6.26
Interest 12.72 36.78 -65.42 497.61 142.99 248.00 497.61 142.99 248.00
PBDT 269.41 208.02 29.51 538.40 962.15 -44.04 538.40 962.15 -44.04
Depreciation 159.48 133.86 19.14 576.09 508.55 13.28 576.09 508.55 13.28
PBT 109.93 74.16 48.23 -37.69 453.60 -108.31 -37.69 453.60 -108.31
TAX 1.05 17.44 -93.98 42.91 111.24 -61.43 42.91 111.24 -61.43
Deferred Tax -38.01 -6.83 456.52 -98.29 30.28 -424.60 -98.29 30.28 -424.60
PAT 108.88 56.72 91.96 -80.60 342.36 -123.54 -80.60 342.36 -123.54
Equity 200.68 17.65 1037.00 200.68 17.65 1037.00 200.68 17.65 1037.00
PBIDTM(%) 17.17 16.88 1.70 16.45 20.33 -19.08 16.45 20.33 -19.08
Read More
May
20
2026
COMPANY Posted on May 20th 2026

Kwality Pharma - Quaterly Results

The sales figure stood at Rs. 1568.22 millions for the March 2026 quarter. The mentioned figure indicates a growth of about 35.57% as compared to Rs. 1156.76 millions during the year-ago period.Profit for the quarter ended March 2026 rises by 74.43% to Rs. 252.90  millions from Rs. 144.99 millions.Operating profit for the quarter ended March 2026 rose to 397.96 millions as compared to 266.64 millions of corresponding quarter ended March 2025.
(Rs. in Million)
  Quarter ended Year to Date Year ended
  202603 202503 % Var 202603 202503 % Var 202603 202503 % Var
Sales 1568.22 1156.76 35.57 5030.59 3701.97 35.89 5030.59 3701.97 35.89
Other Income 10.58 7.65 38.30 28.59 19.20 48.91 28.59 19.20 48.91
PBIDT 397.96 266.64 49.25 1210.88 823.64 47.02 1210.88 823.64 47.02
Interest 28.87 24.92 15.85 109.70 98.78 11.05 109.70 98.78 11.05
PBDT 369.09 241.72 52.69 1092.89 724.86 50.77 1092.89 724.86 50.77
Depreciation 52.61 50.79 3.58 197.94 182.58 8.41 197.94 182.58 8.41
PBT 316.48 190.93 65.76 894.95 542.28 65.03 894.95 542.28 65.03
TAX 63.58 45.94 38.40 221.46 143.38 54.46 221.46 143.38 54.46
Deferred Tax -18.46 -15.87 16.32 -8.87 -15.89 -44.18 -8.87 -15.89 -44.18
PAT 252.90 144.99 74.43 673.49 398.90 68.84 673.49 398.90 68.84
Equity 103.76 103.76 0.00 103.76 103.76 0.00 103.76 103.76 0.00
PBIDTM(%) 25.38 23.05 10.09 24.07 22.25 8.19 24.07 22.25 8.19
Read More
no-content No Records Found

Sign in to Unlock Offers!

Explore Loans, Cards, Investments & Insurance

No SPAM We don't SPAM
Right Hand Side Image
STEP 1/2

Open Demat Account today!

+91

Enter mobile number

Invalid mobile number

Enter Full Name

Invalid Full Name

Verification required
close

Enter the One Time Password (OTP)

Sent to ********99

Edit Number
Enter valid OTP
Field should not be blank
You have exhausted your OTP attempts try again after 10 min

Request another in 60s

Resend OTP

secure   100% safe and secure

Frequently Asked Questions

What is the current share price of Medicamen Organics Ltd. ?

The current share price of Medicamen Organics Ltd. is ₹27.00 as of 2026-05-20.

The market capitalisation of Medicamen Organics Ltd. is ₹31.59 as of 2026-05-18.

The 1-year return of Medicamen Organics Ltd. is 0.00% as of 2026-05-20.

The P/E ratio of Medicamen Organics Ltd. is 6.27 as of 2026-05-20.

The 52-week high and low of Medicamen Organics Ltd. are ₹49.70 and ₹20.05, respectively, as of 2026-05-20.

The dividend yield of Medicamen Organics Ltd. is 0.0% as of2026-05-18.

You can buy Medicamen Organics Ltd. shares through a registered stockbroker or trading platform. Bajaj Markets partners with trusted brokers to help you open a demat account. This is the first step to trading, making it easier to invest in your desired shares.

The Managing Director of Medicamen Organics Ltd. is Bal Kishan Gupta.

When investing in a company’s stock, you may consider key factors such as its fundamentals, including financial health, historical performance, and growth potential. Assess the consistency of its performance, market conditions, and industry trends. Additionally, evaluate your own risk tolerance while reviewing aspects like quarterly earnings, management quality, and sector performance, for taking a well-informed decision.

You can track stock performance on online platforms through live market updates, historical charts, and news alerts. Regular analysis and stock alerts allow you to stay informed about significant price changes and events affecting the stock.

Common stock provides voting rights and the potential for dividends based on company performance, while in case of preferred stock, stockholders receive fixed dividends and have priority over common stockholders in asset distribution but generally lack voting rights.

Stock investments carry market risks, including price volatility, economic shifts, and sector-specific issues. Managing risk can involve diversifying your portfolio, setting stop-loss orders, and staying informed about market trends to make timely decisions.

Market capitalisation, or market cap, is the total value of a company’s outstanding shares and is calculated by multiplying the stock price by the total shares. It classifies companies as large-cap, mid-cap, or small-cap, reflecting their size, stability, and potential risk level in the stock market.

View More

Disclaimer

All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.

The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.

Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform. 

Invalid Mobile Number

Invalid Full Name

Home
Home
ONDC_Shopping
Shopping
Loan
Loan Offers
My Accounts
My Accounts
Explore
Explore